CiToxLAB, a French CRO for non-clinical research, has appointed Philippe Ancian as Senior Director of Biomarkers for the group. Ancian has spent 20 years in the development of biomarkers and specialised genomics and proteomics platforms.
Ancian was Head of Biomarkers at Laboratoires Galderma, then Director of Research and Development for the pharma business unit at Protéus before joining CiT in 2005 to develop the functional genomics platform at the Evreux site in France. He then moved to Transgène in 2010 as Senior Director of the Vectorology and Biomarkers departments, to work on strategy definition and to conduct follow-ups on biomarker and immunomonitoring studies in relation to clinical trials from phases I to III.
Since the acquisition of LAB-Research Group by CiT in 2011, CiToxLAB has invested in the development of a suite of platforms for biomarkers analysis. These include functional genomics, flow cytometry immunophenotyping, mass spectrometry, protein and peptide analysis using multiplex techniques, immunohistochemistry and more recently NGS (Next Generation Sequencing).
